

MINOMIC

More information. Better decisions. Fewer unnecessary biopsies.

INVESTOR TEASER

July 2026

\$3B+

Total addressable market

95%

Test sensitivity — best-in-class

US\$5M

Capital raise over next 18 months

Revenue

Currently generating revenue in market

The Opportunity

THE PROBLEM

Only 1 in 4 men who undergo a prostate biopsy actually have clinically significant cancer.

The other 3 endure a painful, unnecessary \$3,000–5,000 procedure — and today there is no reliable blood test to rule them out beforehand.

1.3M US biopsies/yr · 75% find nothing significant

THE SOLUTION — Minomic and the MiCheck® Prostate test

A cloud-based, patented algorithm blood test which gives urologists a risk-stratification score to confidently defer unnecessary biopsies. Best-in-class specificity and matches the leading competitor on sensitivity.

95% sensitivity · 96–99% NPV · up to 63% fewer biopsies

As a cloud based solution with no COGS, Minomic can rapidly expand globally with no supply chain bottlenecks.

The Abbott based machine which processes the patient blood is owned by the majority of hospitals and urology practices

Minomic has 80% net profit at \$10m gross revenue with the potential to be a dividend paying bio tech company post listing.

Traction — Why Now

- US: Commercial launch underway with DocLab — FDA Q-Sub completed, PLA billing code active, and two physician-owned laboratories operational.
- Australia: Revenue-generating through the Sonic Healthcare commercial channel.
- UK & Europe: Minomic's US competitors are not visibly pursuing the UK/EU market, allowing Minomic to become the dominant blood based test in the UK/EU. Minomic has now executed its partnership arrangement with Addaptive Group Holdings, a leading NHS Trust Provider and a large European diagnostic partner, to accelerate regulatory approval. Preliminary commercialization discussions are now underway with NHS and regional NHS trusts in the UK. Incorporating MiCheck Prostate into the NHS prostate cancer process which could help the NHS remove patients who do not have clinically significant cancer and focus on those males who need clinical support now.
- HK/China/India: Preliminary discussions are now underway to identify a distribution partner for these regions
- US\$10M raised to date (Angels, HNWI's & Family Offices), plus US\$3.5M in government grants and tax incentives.

Market Opportunity & Revenue Trajectory

Market Opportunity · Total TAM \$3B+		3-Yr Revenue — All Markets, Conservative Base Case		
Market	TAM	FY27	FY28	FY29
United States	~\$1.5B	\$5.8M	\$13.2M	\$28.2M
United Kingdom	~\$102M			
Rest of World (ANZ, EU, HK, Japan)	~\$1.4B			

10% of PSA tests estimated eligible for MiCheck® reflex testing · Projections from FY2027; projected FY2026 revenue \$200K

The Moat

Patent-protected 7 patent families, 20+ years R&D, registered across 9+ countries	Regulatory barriers FDA, CE/IVDR and local pathways create multi-year barriers to replication	Exclusive distribution DocLab (US), IDC (UK/EU) and confirmed Asia partners lock in market access	Software economics Cloud-based algorithm — no lab or instrument ownership, negligible COGS
---	---	---	--

The Ask

US\$2.5M (right to accept over subscriptions)	36% FDA Prospective Study	32% Global Commercial Activation
	20% Operations & Working Capital	12% Ex-US Regulatory & Reimbursement
International Investment Bank engaged to investigate a Pre-IPO late 2026 & a listing targeted for 2027.		

Leadership

Sushmita Utpala — CEO Responsible for global commercialisation & market access across FDA and payer pathways Sushmita has previously worked with a US post biopsy diagnosis business which was the subject of a major trade sale for US\$650M after driving strong commercial sales growth	Dr Brad Walsh — Chair & Founder Developed MiCheck® from lab bench to commercial product	David Burdis — CFO Capital management, investor reporting and grant programs	Mark Kogos – Director Capital management, commercialisation and IPO Management with PwC M&A/ITS team and NAB Institutional Bank
---	---	--	---

This document is a summary teaser prepared for qualified investors and does not constitute an offer of securities or investment advice.